SCM
VRTX icon

Silvant Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Silvant Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,731
Closed -$2.16M – 339
2021
Q2 		$2.16M Sell
10,731
-186
-2% -$38.9K 0.34% 71
2021
Q1 		$2.35M Sell
10,917
-345
-3% -$75.8K 0.4% 65
2020
Q4 		$2.66M Buy
11,262
+96
+0.9% +$22K 0.45% 57
2020
Q3 		$3.04M Sell
11,166
-2,995
-21% -$826K 0.57% 41
2020
Q2 		$4.11M Sell
14,161
-949
-6% -$257K 0.74% 30
2020
Q1 		$3.6M Sell
15,110
-299
-2% -$68.6K 0.78% 28
2019
Q4 		$3.37M Sell
15,409
-189
-1% -$38.3K 0.62% 46
2019
Q3 		$2.64M Sell
15,598
-2,130
-12% -$377K 0.52% 58
2019
Q2 		$3.25M Sell
17,728
-1,686
-9% -$295K 0.58% 53
2019
Q1 		$3.57M Sell
19,414
-815
-4% -$151K 0.64% 47
2018
Q4 		$3.35M Sell
20,229
-601
-3% -$104K 0.67% 48
2018
Q3 		$4.01M Sell
20,830
-3,492
-14% -$622K 0.5% 73
2018
Q2 		$4.13M Sell
24,322
-285
-1% -$44.2K 0.51% 74
2018
Q1 		$4.01M Buy
+24,607
New +$4.02M 0.51% 74

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Silvant Capital Management's VRTX Position: Q3 2021 in Review

Silvant Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 10,731 shares — an estimated $2.16M sold.

Silvant Capital Management first reported a position in VRTX in Q1 2018 and held it in 14 quarters. The position peaked at $4.13M in Q2 2018. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Silvant Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Silvant Capital Management sold 10,731 Vertex Pharmaceuticals shares in Q3 2021, an estimated $2.16M.
  • Silvant Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 14 quarters.
  • Silvant Capital Management's Vertex Pharmaceuticals position peaked at $4.13M in Q2 2018.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Silvant Capital Management's 13F filing for Q3 2021, filed 8 Nov 2021.